lapatinib has been researched along with paclitaxel in 90 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 31,874 | 5,729 | 15,395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (16.67) | 29.6817 |
| 2010's | 62 (68.89) | 24.3611 |
| 2020's | 13 (14.44) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Bailey-Downs, LC; Bastian, A; Disch, BC; Dybdal-Hargreaves, NF; Gangjee, A; Hamel, E; Ihnat, M; Mooberry, SL; Raghavan, S; Rohena, CC; Thorpe, JE; Zhang, X | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Cameron, DA; Stein, S | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Huober, J; Spirig, C; Thürlimann, B | 1 |
| Ambudkar, SV; Ashby, CR; Chen, LM; Chen, ZS; Dai, CL; Fu, LW; Huang, Y; Liang, YJ; Liu, DG; Robey, RW; Shi, CJ; Su, XD; Tiwari, AK; Wang, SR; Wu, CP | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z | 1 |
| Amir, E; Freedman, O; Seruga, B; Tannock, I | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Castañeda, CA; Gomez, HL | 1 |
| Arbushites, M; Dering, J; Di Leo, A; Finn, RS; Koehler, M; Oliva, C; Press, MF; Williams, LS | 1 |
| Chen, LM; Chien, AJ; Dubey, S; Fong, L; Huang, Y; Hylton, NM; Illi, JA; Jahan, TM; Kashani-Sabet, M; Ko, AH; Koch, KM; Korn, WM; Moasser, MM; Rosenberg, JE; Ryan, CJ; Small, EJ; Yeh, BM | 1 |
| Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
| Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z | 1 |
| Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Takahashi, H; Toth, G; Tsukuda, M | 1 |
| Vitry, AI | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Boussen, H; Cristofanilli, M; DeSilvio, M; Salazar, V; Spector, N; Zaks, T | 1 |
| Abbey, R; DeSilvio, M; Dobrovolskaya, N; Jagiello-Gruszfeld, A; Manikhas, A; Pienkowski, T; Ridderheim, M; Tjulandin, S | 1 |
| Bethke, K; Cianfrocca, M; Gordon, J; Gradishar, W; Hansen, N; Jeruss, JS; Jovanovic, B; Kaklamani, VG; Khan, SA; Lacouture, M; Meservey, C; Parimi, V; Rosen, S; Scholtens, D; Siziopikou, K; Uthe, R; Von Roenn, J; Wayne, J | 1 |
| Bao, Y; Chang, CJ; Hortobagyi, GN; Hsu, JL; Hung, MC; Lang, JY; Meric-Bernstam, F; Wang, Q; Woodward, WA; Xie, X; Yamaguchi, H; Yu, D | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Bellomo, C; Leporatti, S; Lorusso, V; Lvov, YM; Maffia, M; Rinaldi, R; Tinelli, A; Vergara, D; Vergaro, V; Zhang, X | 1 |
| Aktan, G; Aura, C; Baselga, J; Bradbury, I; Chang, TW; Coccia-Portugal, M; de Azambuja, E; Di Cosimo, S; Dinh, P; Domont, J; Eidtmann, H; Fauria, K; Gelber, RD; Goldhirsch, A; Gómez, H; Horváth, Z; Kunz, G; Lerzo, G; Palacova, M; Piccart-Gebhart, M; Probachai, V; Pusztai, L; Semiglazov, V; Sohn, JH; Tseng, LM; Untch, M; Van Dooren, V | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| Giuliano, M; Schiff, R; Trivedi, MV | 1 |
| Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L | 1 |
| Lim, E; Lin, NU | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Finnie, JW; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM | 1 |
| Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M | 1 |
| Bell, R; Khasraw, M | 1 |
| Bosserman, L; DeSilvio, ML; Hagan, MK; Hart, L; Mahoney, JM; Nagarwala, Y; Richards, P; Salleh, MN; Waterhouse, DM; Yardley, DA | 1 |
| Colon-Otero, G; Dakhil, S; Dueck, AC; Franco, S; Ghanem-Cañete, I; Jenkins, RB; Johnson, D; Kahanic, S; McCullough, AE; Moreno-Aspitia, A; Northfelt, D; Palmieri, FM; Patel, T; Perez, EA; Rodeheffer, R; Tenner, KS | 1 |
| Arpornwirat, W; Chen, G; DeSilvio, ML; Gomez, H; Guan, Z; Jiang, Z; Leung, WL; Lorvidhaya, V; Makhson, A; Newstat, B; Oliva, C; Russo, MW; Shen, Z; Tong, Z; Wang, L; Xu, B; Yang, J | 1 |
| Agbor-tarh, D; Azim, HA; Baselga, J; Bradbury, I; Criscitiello, C; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Piccart, M; Rubio, IT | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W | 1 |
| Abbruzzi, A; Chen, C; Come, SE; Dang, CT; Hudis, CA; Iyengar, NM; Lehman, R; Lin, N; Morris, PG; Moy, B; Norton, L; Oeffinger, KC; Patil, S; Steingart, R; Winer, EP | 1 |
| Aura, CM; Azim, HA; Baselga, J; Bavington, M; Cure, H; de Azambuja, E; Di Cosimo, S; Domont, J; Eidtmann, H; Ellis, C; Ferro, A; Gamez, C; Gebhart, G; Ignatiadis, M; Maetens, M; Piccart-Gebhart, M; Rothé, F; Rouas, G; Sotiriou, C; Toral-Peña, JC; Vuylsteke, P | 1 |
| Atkins, JN; Azar, CA; Baez-Diaz, L; Bandos, H; Bear, HD; Brufsky, AM; Costantino, JP; Farrar, WB; Fehrenbacher, L; Geyer, CE; Mamounas, EP; Margolese, RG; Paik, S; Rastogi, P; Robidoux, A; Sarwar, S; Shibata, HR; Swain, SM; Tang, G; Wolmark, N | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Anderson, T; Blum, JL; Danso, M; Espina, V; Florance, A; Holmes, FA; Krekow, L; Liotta, LA; Mahoney, J; McIntyre, KJ; Nagarwala, YM; O'Shaughnessy, JA; Osborne, CR; Pippen, J | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Bang, YJ; Chung, HC; Chung, IJ; Doi, T; Feng, JF; Kobayashi, M; Li, J; Miwa, H; Mukaiyama, A; Ohtsu, A; Omuro, Y; Qin, SK; Satoh, T; Sun, GP; Tsuji, A; Wang, JW; Xu, JM; Xu, RH; Yeh, KH | 1 |
| Bateman, E; Bowen, JM; Boyle, FM; Keefe, DM; Mayo, BJ; Plews, E; Stringer, AM; Wignall, A | 1 |
| DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J | 1 |
| Cao, S; Jiang, X; Wang, F; Wang, Y; Wei, Y; Xiong, Y; Xu, S; Zhang, Q; Zhang, S; Zou, A | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S | 1 |
| Bekki, K; Haarmann-Stemmann, T; Ito, T; Li, W; Matsumura, F; Sweeney, C; Vogel, CF; Vogel, H | 1 |
| Chen, Z; Dai, C; Fu, L; Huang, Z; Ma, S; To, K; Wang, F; Wu, X; Zhao, H | 1 |
| Dorkoosh, FA; Kelishadi, PD; Ravar, F; Saadat, E | 1 |
| Baselga, J; Chen, MF; Comen, EA; D'Andrea, GM; Dang, CT; Drullinsky, PR; Fornier, MN; Gajria, D; Goldfarb, SB; Hudis, CA; Iyengar, NM; Lacouture, ME; Lake, DE; Modi, S; Norton, L; Patil, S; Sugarman, SM; Theodoulou, M; Traina, TA; Troso-Sandoval, TA | 1 |
| Dai, W; He, B; Hu, H; Lin, Z; Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Dang, C; Friedman, MD; Lacouture, M | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Dehghankelishadi, P; Dorkoosh, FA; Gholami, M; Pordeli, M; Ravar, F; Saadat, E; Safavi, M | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Bando, H; Inoue, K; Iwata, H; Kasai, H; Kuroi, K; Masuda, N; Morita, S; Ohno, S; Ohtani, S; Sakurai, T; Takano, T; Toi, M; Yamamoto, N; Yanagita, Y | 1 |
| Dou, QH; Guo, XF; Li, SS; Liu, D; Zhu, XF | 1 |
| Bowen, JM; Chung, R; Keefe, DMK; Lee, AMC; Plews, E; Su, YW; Xian, CJ | 1 |
| Adamchuk, H; Baselga, J; Boyle, F; Ciruelos, E; Dasappa, L; de Azambuja, E; de la Pena, L; Di Cosimo, S; Fumagalli, D; Gelber, RD; Hackman, J; Hickish, T; Holmes, E; Huober, J; Jackisch, C; Jouannaud, C; Lang, I; Lecocq, C; Piccart-Gebhart, M; Sarp, S; Smith, I; Toral Pena, JC; Untch, M; Wildiers, H; Xu, B | 1 |
| Belcheva, A; Boone, T; Chang, JC; Creamer, SL; Darcourt, JG; Ensor, JE; Kaklamani, VG; Kuhn, JG; Li, X; Meisel, JL; Niravath, PA; Patel, TA; Qian, W; Rodriguez, AA; Rosato, RR; Schwartz, MR; Zhao, J | 1 |
| Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
| Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
| Bazrgar, M; Hassani, SN; Masoudi, NS; Mirzaei-Seresht, B; Mollammohammadi, S; Sheidai, M | 1 |
| Berry, D; Carey, LA; Dang, C; Fernandez-Martinez, A; Hahn, O; Harris, L; Henry, NL; Hillman, DW; Hoadley, KA; Hudis, C; Huebner, L; Krop, IE; Parker, JS; Partridge, A; Perou, CM; Polley, MY; Shepherd, J; Tolaney, S; Winer, E | 1 |
| Nycz, J; Wilczok, A; Zajdel, A | 1 |
| Agarwal, R; Grieb, BC | 1 |
| Chen, T; He, Y; Lu, H; Pang, Z; Wang, Y | 1 |
| Alba, E; Antolin, S; Barnadas, A; Bonfill, X; Lluch, A; Martin, M; Rodriguez-Lescure, A; Ruiz-Borrego, M; Sanchez-Rovira, P; Servitja, S; Sola, I; Urrutia, G; Vazquez, JC | 1 |
| Ballman, KV; Brasó-Maristany, F; Campbell, JD; Carey, LA; Chic, N; Cortés, J; Fernandez-Martinez, A; Hoadley, KA; Krop, I; Llombart-Cussac, A; Nuciforo, P; Pare, L; Partridge, A; Pascual, T; Perou, CM; Prat, A; Rashid, NU; Singh, B; Spears, PA | 1 |
| Anderson, RA; Arecco, L; Ballestrero, A; Bruzzone, M; Cameron, DA; Ceppi, M; de Azambuja, E; Del Mastro, L; Demeestere, I; Di Cosimo, S; El-Abed, S; Franzoi, MA; Lambertini, M; Latocca, MM; Lecocq, C; Massarotti, C; Nuciforo, P; Partridge, AH; Peccatori, FA; Piccart, M; Pistilli, B; Pusztai, L; Rolyance, R; Ruddy, KJ; Saura, C; Sohn, J; Untch, M; Wang, Y | 1 |
| Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K | 1 |
14 review(s) available for lapatinib and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lapatinib; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Neoplasm; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lapatinib; Oxaliplatin; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab | 2021 |
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
34 trial(s) available for lapatinib and paclitaxel
| Article | Year |
|---|---|
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2008 |
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2009 |
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Topics: Administration, Oral; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Injections, Intravenous; Lapatinib; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2009 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2010 |
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome | 2010 |
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Inflammation; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines | 2010 |
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Latvia; Middle Aged; Paclitaxel; Poland; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Romania; Russia; Up-Regulation | 2010 |
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lapatinib; Liver; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Nausea; Paclitaxel; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2013 |
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Up-Regulation | 2013 |
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Decision Making; Female; Humans; Lapatinib; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Failure; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2013 |
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Lapatinib; Logistic Models; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Puerto Rico; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT5 Transcription Factor; Trastuzumab | 2013 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Odds Ratio; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2014 |
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate | 2015 |
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2016 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Trastuzumab | 2016 |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre,
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Lapatinib; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Trastuzumab | 2019 |
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome; Tumor Burden | 2019 |
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Transcriptome; Trastuzumab; Young Adult | 2020 |
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Immunoglobulin G; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Transcriptome; Trastuzumab; Treatment Outcome | 2023 |
42 other study(ies) available for lapatinib and paclitaxel
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Solubility; Structure-Activity Relationship; Water | 2014 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2022 |
[New treatment approaches in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2008 |
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Paclitaxel; Quinazolines; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Quinazolines | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2009 |
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome | 2010 |
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Lapatinib; Mice; Paclitaxel; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2010 |
Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Paclitaxel; Periodicals as Topic; Quinazolines; United States; United States Food and Drug Administration | 2010 |
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Claudin-4; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2011 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colloids; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Nanocapsules; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2012 |
Die and let live: harnessing BikDD to combat breast cancer stem cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; CD24 Antigen; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; Lapatinib; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases | 2012 |
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms | 2012 |
Predicting drug responsiveness in human cancers using genetically engineered mice.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment | 2013 |
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Models, Animal; ErbB Receptors; Goblet Cells; Intestinal Mucosa; Intestines; Lapatinib; Male; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2 | 2014 |
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Combinations; Drug Compounding; Endocytosis; Female; Humans; Lactic Acid; Lapatinib; Micelles; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Quinazolines; Receptor, ErbB-2; Solubility; Surface Properties | 2015 |
The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lapatinib; Paclitaxel; Polychlorinated Dibenzodioxins; Quinazolines; Receptors, Aryl Hydrocarbon; RNA, Messenger; RNA, Small Interfering; Transcription Factor RelB; Ultraviolet Rays | 2015 |
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Interactions; Female; Hepatocytes; Humans; Immunohistochemistry; Lapatinib; Mice; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Compounding; Drug Delivery Systems; Lapatinib; Liposomes; Mice; Paclitaxel; Particle Size; Quinazolines; Structure-Activity Relationship; Surface Properties | 2016 |
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Survival; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Compounding; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Hydrogels; Injections, Intralesional; Injections, Intravenous; Lapatinib; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel; Poloxamer; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Solubility; Technology, Pharmaceutical; Temperature; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles.
Topics: Animals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Hemolysis; Lapatinib; Male; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Poloxamer; Quinazolines; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Esophageal Squamous Cell Carcinoma; Female; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats.
Topics: Adiposity; Animals; Bone Marrow; Bone Morphogenetic Proteins; Bone Resorption; Drug Therapy, Combination; Gene Expression; Genetic Markers; Intercellular Signaling Peptides and Proteins; Lapatinib; Membrane Proteins; Paclitaxel; PPAR gamma; Protein Kinase Inhibitors; Rats; Rats, Wistar; Survivin; Transcription Factors; Tubulin Modulators; Wnt Proteins; Wnt Signaling Pathway | 2019 |
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Chromosomal instability reducing effect of paclitaxel and lapatinib in mouse embryonic stem cells with chromosomal abnormality.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line; Chromosomal Instability; Lapatinib; Mice; Mouse Embryonic Stem Cells; Nanog Homeobox Protein; Octamer Transcription Factor-3; Paclitaxel; SOXB1 Transcription Factors | 2020 |
Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Female; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors | 2021 |
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intravenous; Lapatinib; Mice; Micelles; Paclitaxel; Peptides; Tumor Cells, Cultured | 2022 |
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Topics: Adult; Biomarkers; Breast Neoplasms; Female; Humans; Lapatinib; Ovarian Reserve; Paclitaxel | 2023 |
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites | 2023 |